More than 130 million people worldwide chronically infected with hepatitis C virus (HCV) are at risk of developing severe liver disease. Antiviral treatments are only partially effective against HCV infection, and a vaccine is not available. Development of more efficient therapies has been hampered by the lack of a small animal model. Building on the observation that CD81 and occludin (OCLN) comprise the minimal set of human factors required to render mouse cells permissive to HCV entry 1 , we previously showed that transient expression of these two human genes is sufficient to allow viral uptake into fully immunocompetent inbred mice 2 . Here we demonstrate that transgenic mice stably expressing human CD81 and OCLN also support HCV entry, but innate and adaptive immune responses restrict HCV infection in vivo. Blunting antiviral immunity in genetically humanized mice infected with HCV results in measurable viraemia over several weeks. In mice lacking the essential cellular cofactor cyclophilin A (CypA), HCV RNA replication is markedly diminished, providing genetic evidence that this process is faithfully recapitulated. Using a cell-based fluorescent reporter activated by the NS3-4A protease we visualize HCV infection in single hepatocytes in vivo. Persistently infected mice produce de novo infectious particles, which can be inhibited with directly acting antiviral drug treatment, thereby providing evidence for the completion of the entire HCV life cycle in inbred mice. This genetically humanized mouse model opens new opportunities to dissect genetically HCV infection in vivo and provides an important preclinical platform for testing and prioritizing drug candidates and may also have utility for evaluating vaccine efficacy.
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The narrow species tropism of HCV is incompletely understood. Mouse cells do not support viral entry and inefficiently replicate HCV RNA, but do support virion assembly and release. HCV uses numerous cellular factors to enter hepatocytes in a coordinated multistep process, including glycosaminoglycans 3 , low-density lipoprotein receptor 4 , scavenger receptor class B type I (SCARB1) 5 , the tetraspanin CD81 (ref. 6) , the tight junction proteins claudin 1 (CLDN1) 7 and occludin (OCLN) 1, 8 , the receptor tyrosine kinases epidermal growth factor receptor 9 and ephrin receptor A2 (ref. 9) , and the cholesterol uptake receptor Niemann-Pick C1 like 1 (ref. 10) . Of these, CD81 and OCLN comprise the minimal human factors needed for HCV uptake into rodent cells 1 .
We recently demonstrated that adenoviral delivery of HCV entry factors renders mice susceptible to HCV infection 2 . This transient approach is high-throughput and allows the possibility of rapidly evaluating mutant versions of HCV entry factors. However, adenoviral gene delivery strongly induces interferon-stimulated genes, creating an environment that may antagonize HCV replication. To limit variability and to prevent vector-mediated immune activation, we generated transgenic mice stably expressing human CD81, SCARB1, CLDN1 and/or OCLN under the control of a liver-specific albumin promoter.
Transgenic expression of the human orthologues of the HCV entry factors resulted in similar mRNA levels of the human and endogenous mouse genes in the murine liver ( Supplementary Fig. 1 ) and expression of all four proteins ( Supplementary Fig. 2 ) with the expected subcellular distribution in the liver ( Supplementary Fig. 3 ). Next, we aimed to test the susceptibility of entry factor transgenic (EFT) mice to HCV infection. To identify founder lines supporting viral entry we took advantage of a previously generated, highly sensitive detection system which is based on the activation of a loxP-flanked STOP-luciferase reporter in the genome of ROSA26-Fluc mice by Cre recombinase encoded in recombinant HCV genomes 2 . We crossed EFT mice to a ROSA26-Fluc background and challenged these animals with a bicistronic HCV genome expressing Cre (HCV-Cre). Consistent with previous data 2 , the bioluminescent reporter was activated in mice expressing human CD81 and OCLN ( Fig. 1a and Supplementary Fig. 4a ). The addition of human SCARB1 and CLDN1 ( Supplementary Fig. 4b ) did not increase the entry signal, demonstrating that their murine orthologues are functional for HCV entry in vivo. For subsequent experiments, founder lines Alb-hCD81/hOCLN#941 (2hEF) and Alb-hCD81/hSCARB1/ hCLDN1/hOCLN#100 (4hEF), which supported the most efficient viral uptake ( Supplementary Fig. 4a ), were used. To estimate the number of HCV-infected liver cells, we used an indicator mouse strain in which Cre leads to activation of a nuclear-localized green fluorescent protein/b-galactosidase (GNZ) reporter (ROSA26-GNZ) 11 . Similar to our previous observations 2 , HCV-Cre infection resulted in reporter activation in approximately 1-1.5% of murine hepatocytes in 2hEF or 4hEF mice ( Fig. 1b and Supplementary Fig. 5 ). To provide additional evidence that viral uptake into EFT mice is mediated by the specific interaction of HCV glycoproteins with host entry factors, we administered antibodies directed against the HCV envelope glycoprotein complex E1E2 or the host entry factor CD81. Delivery of anti-human CD81 or anti-E1E2 (AR4A; ref. 12) antibodies resulted in a dose-dependent inhibition of HCV-Cre infection ( Fig. 1c ), whereas isotype control immunoglobulins had no effect. These data further affirm that HCV is taken up in a viral glycoprotein-specific fashion in vivo and underscore the utility of this model for evaluation of passive immunization strategies.
Direct measurement of HCV genome levels by quantitative reverse transcription (qRT)-PCR demonstrated a slight increase in HCV RNA in the serum (at 4 h) and liver (at 3 h and 24 h) of inoculated mice expressing the human entry factors; at 72 h, however, the signal was reduced to background levels ( Fig. 1d, e ). HCV infection resulted in the upregulation of several interferon-stimulated genes (Fig. 1f, g and Supplementary Fig. 6 ), infiltration of immune cells, especially natural killer (NK) cells, into the liver (Fig. 1i ), and elevated proinflammatory cytokine levels in the serum ( Fig. 1h and Supplementary  Fig. 7 ), which could antagonize HCV replication. This hypothesis is further supported by the previous observation that HCV replicons, selectable HCV RNA genomes, replicate more efficiently in murine cells with impaired antiviral signalling 13, 14 .
To identify a murine environment more conducive to HCV replication we crossed 4hEF ROSA26-Fluc mice to strains carrying targeted disruptions in Eif2ak2, Mavs, Irf1, Irf3, Irf7, Irf9, Stat1 or the Ifn-ab receptor (Fig. 2 ). These strains are viable and known to be hypersusceptible to RNA viruses, due to impaired innate immune responses. The luminescent reporter signal was slightly elevated during the early phase after infection with HCV-Cre in most EFT strains impaired in antiviral signalling as compared to EFT mice on a wild-type background ( Fig. 2a-d ). Between 20 and 40 days after infection there was a marked increase in the luciferase signal, particularly in IRF1 (eightfold), IRF7 (16-fold) ( Fig. 2c ), IFN-abR (20-fold) and STAT1 (40-fold) deficient mice ( Fig. 2d ) compared to non-transgenic littermate controls. The increased reporter signal, which presumably reflects a transient burst in viral replication and spread, eventually returned to background levels, possibly marking clearance of HCV-infected cells by the murine immune system. The elevated luminescent signal correlated with increases in serum HCV RNA levels at peak time points ( Fig. 2e ).
To validate that the elevated signal is indeed due to increased HCV RNA replication in mice with blunted antiviral immunity, we crossed cyclophilin A (CypA)-deficient mice (Ppia 2/2 ) to the EFT ROSA26-Fluc Stat1 2/2 background. CypA is a critical host factor for HCV RNA replication in human cells 15 . In Ppia 2/2 4hEF ROSA26-Fluc Stat1 2/2 mice HCV RNA ( Fig. 3c ) and the luminescent reporter signal at peak times (day 31) was more than 60% lower than that of Ppia 1/1 and Ppia 1/2 mice ( Fig. 3d ), probably as a direct consequence of the murine PPIA deficiency. These data provide the first direct genetic evidence that CypA is a bona fide HCV replication factor in vivo. Furthermore, treatment of 4hEF Stat1 2/2 mice with an NS5A inhibitor for 3 weeks after infection suppressed HCV RNA loads to below the limit of detection ( Fig. 3e ), providing additional evidence that HCV RNA does indeed replicate in these mice.
Unambiguous detection of HCV antigens in situ is difficult. Therefore, we constructed a transgenic mouse line expressing a modified version of a previously described cell-based fluorescent reporter system 16 to visualize infection directly in the liver of infected mice (Supplementary Fig. 8 ). This highly sensitive reporter, the activity of which directly correlates with the level of HCV RNA replication, is based on cleavage of a blue fluorescent protein (TagBFP)-MAVS fusion protein by the HCV NS3-4A serine protease and translocation of the mitochondrially anchored fluorescent protein to the nucleus. The chimaeric TagBFP-nlsMAVS protein was widely expressed in the liver as assessed by histology and flow cytometry ( Supplementary Fig. 8a, b ). To quantify HCV protease-mediated nuclear re-localization accurately we subjected single hepatocyte suspensions to ImageStream X analysis. Adenovirusmediated overexpression of NS3-4A activated the reporter in a majority of cells ( Supplementary Fig. 9 ), demonstrating the functionality of the reporter in vivo. In EFT 1 but not EFT 2 (Fig. 3a ) TagBFP-nlsMAVS transgenic mice HCV infection causes overlap of TagBFP fluorescence with the nuclear counterstain in approximately 0.2% of the cells (Fig. 3b ). This low but HCV-specific reporter activation is probably due to the limited amounts of NS3-4A being translated from the incoming viral RNA, which cannot accumulate as a consequence of the abortive presumably single-cycle infection on a fully immunocompetent background. In contrast, crossing the EFT 1 TagBFP-nlsMAVS strain to a Stat1-null background increased the frequency of cells displaying HCV infection twofold over STAT1-positive controls (to 0.4%). Notably, whereas the reporter was activated only transiently 64 
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in STAT1 sufficient mice, the signal persisted at least until day 10 in mice on a Stat1 2/2 background (Fig. 3b ). Taken together, these results indicate that HCV can replicate in immunocompromised mice expressing human CD81 and OCLN and highlight the value of the model for studying HCV replication in vivo.
We further characterized viral kinetics in mice infected with a monocistronic cell-culture-derived HCV (HCVcc). HCV RNA rose approximately tenfold over the limit of quantification in serum (Fig. 4a, c) and liver (Fig. 4b, d ) of EFT Stat1 2/2 mice as compared to non-transgenic Stat1 2/2 controls. Mice remained persistently infected for most of the observation period, with HCV RNA becoming nearly undetectable after 90 days (Fig. 4c, d) . Sequence analysis of HCV RNA detected at late time points in mice infected with HCV-Cre revealed mutations in some viral genomes, but none was shared among the five mice that were analysed ( Supplementary Fig. 12 ). Whether any of these are adaptive mutations that increase viral fitness in vivo will be the subject of future studies. HCV infection caused splenomegaly in some innate immune-deficient mice expressing HCV entry factors, but not in non-EFT mice ( Supplementary Fig. 10a ), indicative of HCV-specific immune activation. Indeed we observed increased frequencies of NK cells and subsequently B cells in the spleens of 4hEF Stat1 2/2 mice in the early and late phases of infection, respectively ( Fig. 4e and Supplementary  Fig. 10b ). Consistent with results in humans and chimpanzees, primarily NK and IFN-c-producing CD8 1 T cells (Fig. 4f ) infiltrated the livers of 4hEF Stat1 2/2 mice with a skewing towards an effector memory phenotype near the end of the time course ( Supplementary Fig. 10c ). These data indicate that HCV infection elicits cellular immune responses, albeit potentially confounded by the STAT1 deficiency, which may contribute to eventual viral clearance.
To determine whether primary hepatocytes in EFT mice on immunodeficient backgrounds were capable of producing infectious virions, sera collected at day 40 after infection were used to inoculate naive Huh-7.5 cells. Infectious virus was detected in sera of 4hEF mice deficient for STAT1, IRF1 and IRF7 (Fig. 5a ), consistent with the increased levels of luminescent reporter activity (Fig. 2c, d) and HCV RNA load ( Fig. 2e ) in these strains. In HCV-infected 4hEF Stat1 2/2 mice titres reached approximately 100 tissue culture infectious dose 50 (TCID 50 ) per ml (Fig. 5b) . Sera from HCV-infected non-EFT littermates, or directly acting antiviral (DAA)-treated 4hEF Stat1 2/2 or 4hEF Stat1 2/2 Ppia 2/2 mice collected at the same time points, did not yield NS5A-positive cells (data not shown), indicating de novo virus production rather than carry-over of the inoculum. To demonstrate that the lack of HCV NS5A-positive cells in the infectivity assay cannot simply be attributed to residual quantities of the DAA in circulation, we spiked the sera from the BMS-790052-treated animals with tissue-culture-produced BiCre-Jc1 virus (Fig. 5b) and found no inhibitory effect. Furthermore, in Huh-7.5 cells expressing an TagRFP-nlsMAVS reporter 16 , infection with sera from infected mice resulted in re-localization of the reporter signal whereas inoculation with sera from non-infected, DAA-treated or Ppia 2/2 mice did not ( Supplementary Fig. 11 ). These data are in accordance with previous in vitro observations demonstrating that mouse hepatoma cells support late stages of the HCV life cycle 17 .
This study represents an important step forward in developing an animal model for HCV infection and immunity. To our knowledge this is the first time that the entire HCV life cycle has been recapitulated in inbred mice with inheritable susceptibility to HCV. Previously developed xenotransplant mouse models can also be infected with HCV. However, these models are hampered by intra-and inter-experimental variability, donor-to-donor variability, low throughput, and high costs. The inbred mouse model presented here can overcome many of these challenges, is amendable to genetic manipulations and can be used for preclinical assessment of the efficacy of antiviral drug candidates and entry inhibitors. To study unperturbed HCV-specific immune responses and HCV-associated pathogenesis it will be necessary to establish persistent HCV infection in fully immunocompetent mice. By harnessing the remarkable genetic plasticity of HCV it may be possible to select for viral variants that replicate more robustly in sufficiently immunocompromised rodent strains. High titre sera could subsequently be passaged through progressively more immunocompetent hosts to produce this outcome. Future studies will address the capacity of different, genetically diverse HCV genotypes to establish chronicity in genetically humanized mice.
METHODS SUMMARY
Mice. Construction of all mice expressing HCV entry factors under the control of a liver-specific albumin promoter or CAGGS-TagBFP-nlsMAVS and the source of all other mouse mutant strains is described in the Methods. Mice were bred and maintained at the Comparative Bioscience Center of The Rockefeller University according to guidelines established by the Institutional Animal Committee. Hepatitis C virus. Plasmids encoding chimaeric HCV genomes, including Jc1, Con1-Jc1 and bicistronic HCV genomes expressing Cre, were linearized with XbaI and in vitro transcribed. RNA was electroporated into Huh-7.5 cells and infectious virus was collected from supernatants 48-72 h after transfection 18 . RT-PCR quantification of HCV RNA. Total RNA was isolated from mouse brain, liver and sera using the RNAeasy kit (Qiagen). HCV genome copy number was quantified by one-step RT-PCR. 
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Biosciences (for western blotting). The HCV NS5A inhibitor BMS-790052 (ref. 41) was obtained from Selleck Chemicals. Adenovirus constructs. Adenoviral constructs encoding HCV JFH1 NS3-4A were created using the AdEasy Adenoviral Vector System (Agilent Technologies) according to the manufacturer's instructions. Briefly, JFH1 NS3-4A cDNA was PCR-amplified from pCR3.1-NS3/4A and inserted into the pShuttle-CMV using KpnI/NotI sites. Recombinant pShuttle-CMV plasmids were linearized with PmeI and ligated to pAdEasy by homologous recombination followed by electroporation into BJ5183 cells (Agilent). Recombinant pShuttle-pAdEasy constructs were identified by PacI restriction analysis. All plasmid constructs were verified by DNA sequencing. Histological detection of HCV entry factors. Liver and spleen of mice injected with adenoviruses encoding human entry factors were collected 24 h after injection and fixed using 4% paraformaldehyde. Tissue sections (8 mm) were deparaffinized and subjected to antigen retrieval by boiling for 30 min in citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0). Entry factors were stained with human-specific primary antibodies for 16 h at 4 uC followed by secondary antibody staining using Alexa 488 or Alexa 633-conjugated antibodies for 2 h at room temperature. For in situ detection of eGFP fluorescence, mouse tissue was immediately frozen in OCT (Optimal Cutting Temperature) compound at 280 uC. Tissue sections (,5-6 mm) were cut on poly-L-lysine-coated slides. Secondary antibodies goat-anti-mouse or goat-anti-rabbit Alexa 488-or rhodamine conjugates (Invitrogen; 1:1,000) were used for immunofluorescence. Nuclei were detected using DAPI in VectaShield Mounting medium (Vector Laboratories). Images were captured on an Axioplan 2 imaging fluorescence microscope (Zeiss) using Metavue Software (Molecular Devices). Images were processed using ImageJ software (NIH). Isolation of murine hepatocytes. Mice were anaesthetized by intraperitoneal injection of a mixture of 100 mg kg 21 ketamine and 10 mg kg 21 xylazine. Livers were perfused through the inferior vena cava for 5 min each with chelating buffer (0.5 mM EGTA, 0.05 M HEPES pH 7.3 in Ca/Mg-free HBSS) at a flow rate of 2 ml min 21 followed by collagenase solution (4.8 mM CaCl 2 , 100 U ml 21 collagenase type IV, 0.05 M HEPES pH 7.3 in Ca/Mg-free HBSS). The resulting cell suspension was passed through a 100 mm cell strainer, washed twice in HBSS and was fixed in 4% paraformaldehyde. Purity of isolated hepatocytes was over 90% in all preparations as confirmed by intracellular staining for murine albumin. Immune activation. Lymphocytes were isolated from liver and spleen by digestion with 0.1% collagenase (Sigma) for 30 min at 37 uC. Lymphocytes were then isolated from the cell suspensions as well as from peripheral blood by density gradient centrifugation. Cells were stained with directly fluorochrome-conjugated antibodies against CD3, CD4, CD8, B220 (eBioscience) and NKp46 (BD Biosciences). After cell surface staining, cells were fixed and permeabilized using BD Cytofix/ Cytoperm (BD Biosciences) and stained with antibodies against IFN-c and TNF-a. Samples were measured using a BD LSR2 flow cytometer (BD Biosciences) and data were analysed using Flowjo (Treestar Software). Western blotting. Perfused murine liver tissue was homogenized in lysis buffer containing 1% Triton X-100, 50 mM Tris-HCl pH 8, 150 mM NaCl and Mini EDTA-free Protease Inhibitor Cocktail (Roche) for 30 min on ice. Thirty micrograms of protein lysate was separated on 4-12% Bis/Tris NuPage polyacrylamide gels (Invitrogen). Proteins were transferred to nitrocellulose membranes and entry factors were detected using antibodies against human SCARB1 (1:500) and CLDN1 (1:200). b-actin (1:10,000) was probed as a loading control. After secondary antibody staining with HRP-conjugated anti-mouse IgG Fc (JIR, 1:10,000), western blots were visualized using SuperSignal West Pico (Thermo Scientific). RT-PCR quantification of HCV entry factors and interferon-stimulated genes. To quantify expression of human and murine genes (entry factors and interferon-stimulated genes), the livers of FVB/NJ mice were collected at the indicated time points. Total liver RNA was isolated using RNeasy isolation kit (Qiagen) and cDNA was synthesized from 0.5 mg RNA using a SuperScript VILO cDNA Synthesis kit (Invitrogen) according to manufacturer's instructions. Quantitative PCR was performed with a light cycler LC480 (Roche Applied Science) using an Applied Biosystems SYBR Green PCR Master Mix and the following primer 
